openPR Logo
Press release

RNA Therapeutics 2020 to Highlight Downregulating Therapeutic Technologies

11-08-2019 03:35 PM CET | Health & Medicine

Press release from: SMI

RNA Therapeutics 2020

RNA Therapeutics 2020

SMi Reports: The morning session on day two of SMi’s RNA Therapeutics conference will pay a particular focus to “Downregulating Therapeutic Technologies”.

SMi are proud to host the 11th annual RNA Therapeutics conference on February 19th – 20th 2020 in London. This year’s event will maintain a focus on the latest research and developments on delivery system technologies aimed at tackling difficult targets within the human body.

An early bird savings of £200 expires on 29th November. Interested parties are encouraged to register early at www.therapeutics-rna.com/openpr4

The conference will pay close attention to regulations within the field of RNA Therapeutics, such as, continuing upon patenting novel products, the release of new 2020 regulations in the clinical trials arena and ensuring compliance. The agenda for the morning of day two will highlight “Downregulating Therapeutic Technologies”.

Session Highlights Include:

MiRNA Therapeutics: From Discovery to the Bedside

• The non-coding genome makes up 98.8% of the human genome. Most of this non-coding genome is transcribed into non-coding RNAs that may play an important role in cellular regulation in health and disease; these non-coding RNAs could be novel targets for future medicines.
• MicroRNAs are short non-coding RNAs that regulate biochemical pathways and networks of pathways by the mechanism of RNA interference (RNAi). MicroRNA-21 has been implicated in multiple organs as a microRNA associated with fibrotic diseases and cancer.
• The presentation will summarise the opportunities and challenges of developing microRNA-based drugs and will illustrate the successful generation of an anti-fibrotic microRNAbased therapeutic approach by targeting microRNA-21 with an antisense oligonucleotide (anti-miR-21). This microRNA-based drug is now in a phase 2 clinical trial for a fibrotic kidney disease called Alport Syndrome.
Ekkehard Leberer, Senior Director, Alliance Management, Sanofi

MicroRNA Replacement Therapy: Myth or Reality?

• miRNAs - Mother Nature has already done most of the job! ...
• miRNAs as novel therapeutic intervention in Oncology
• miRNA replacement therapy (miRNA mimics)
Michel Janicot, Chief Development Officer, InteRNA Technologies

NanoGenics; Using a peptide nanoparticle, LipTide, to develop a siRNA product portfolio
• How does the peptide nanoparticle, LipTide resemble an artificial virus?
• Delivering siRNA with LipTide across multiple administration routes
• Case study; Targeting the MRTF pathway to develop siRNA anti-fibrotic drugs

Simon Newman, CSO, Nanogenics

This year’s agenda also includes a Focus Day held the 18th of February including sessions on recent developments in “Oligonucleotide Delivery Systems”.

View the full event programme at www.therapeutics-rna.com/openpr4

RNA Therapeutics
Focus Day: 18th February 2020
Conference: 19th – 20th February 2020
Copthorne Tara Hotel, London, UK

Proudly sponsored by:
ChemGenes | Thermo Fisher Scientific

--- ENDS –
Contact Information:
For media enquiries contact Alia Malick on +44 (0)20 7827 6168
For all delegate enquiries, contact Hakam Panum on +44 (0)20 7827 6128

About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

45 Curlew Street

About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release RNA Therapeutics 2020 to Highlight Downregulating Therapeutic Technologies here

News-ID: 1864104 • Views: 153

More Releases from SMI

Registration closing soon for SMi’s Social Media in the Defence and Military S …
SMi reports: Two weeks left to secure your place at the upcoming 9th annual Social Media in the Defence Sector conference, taking place in London Taking place on 20th and 21st November, the 9th annual Social Media in the Defence Sector conference, taking place in London, will feature the biggest speaker line-up to date, with leading militaries at the cutting edge of social media innovation from the UK, USA, Canada, Italy,
11-01-2019 | Health & Medicine
SMI
Exclusive interview from conference speaker John Lisman released ahead of Parall …
SMi has released an exclusive interview with industry expert John Lisman, Attorney, Consultant and Trainer of Lisman Legal Life sciences B.V., ahead of the upcoming Parallel Trade conference this February. SMi’s Parallel Trade conference, taking place on 4th-5th February 2020 in London, will explore shortages of medicines, current and ongoing challenges posed by Parallel Trading, potential implications of Brexit and IP exhaustion rights. As the only B2B parallel trade conference in
11-01-2019 | Health & Medicine
SMI
Exclusive interview from conference speaker Torsten Kneuss released ahead of SMi …
SMi has released an exclusive interview with industry expert Torsten Kneuss, Quality Assurance Manager Combination Products of Bayer, ahead of the upcoming Pre-Filled Syringes and Injectable Drug Devices conference this January. SMi’s Pre-Filled Syringes and Injectable Drug Devices conference, taking place on 15th-16th January 2020 in London, will bring together pharmaceutical experts, clinical researchers and manufacturers in the pre-filled syringes industry to examine innovations in device engineering and components, enhancement of
Registration has opened for the 2020 edition of Defence Logistics Central and Ea …
SMi Group reports: Defence Logistics Central and Eastern Europe returns for it’s 5th successful year in March 2020 SMi Group presents the 5th annual Defence Logistics Central and Eastern Europe, taking place in Budapest, Hungary on 3rd and 4th March 2020. As the need for armed forces to enhance and maximise their logistical capacity continues to grow, and with the current political climate in Europe, it is now more important than ever

All 5 Releases


More Releases for RNA

RNA Therapy Improves Vision in Child Blindness, hear more about recent developme …
SMi Reports: In light of recent developments in the field of RNA Therapy, SMi’s 10th Annual RNA Therapeutics is set to deliver the latest advancements in February this year. Leber congenital amaurosis (LCA), one of the most common causes of blindness in children, has been the subject of successful RNA therapy as researchers at the University of Pennsylvania recently published new data showing the success of the new therapy which improved
Automated DNA/RNA Isolation System Market Overview Till 2018-2023
Future Market Reports on Global Automated DNA/RNA Isolation System 2018 Research Report presents a professional and complete analysis of on the current Industry situation. The Global report includes Automated DNA/RNA Isolation System Revenue, market Share, industry volume, Trends, Growth aspects. It analyses the important factors of the based on present industry situations, demands, business strategies utilized by Automated DNA/RNA Isolation System market players and the future prospects from various angles
RNA Sequencing: Technologies and Analyses of Global Market Trends
"The Latest Research Report RNA Sequencing: Technologies and Global Markets provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" The global RNA-Sequencing market reached nearly $1.1 billion in 2015, and should reach $1.2 billion in 2016 and $2.1 billion in 2020, registering a compound annual growth rate (CAGR) of 14.9%. The tools and reagents segment should reach over $1.0 billion in 2020 from $566.8
Topics Presented this February 2018 at RNA Therapeutics
SMi’s RNA Therapeutics will be bringing a global presence from MHRA, The RNA Institute, MiNA Therapeutics, AstraZeneca R&D, GSK, Sanofi, CureVac and more. With an agenda full of exciting and new approaches, examine the latest developments in delivery systems for RNA Therapeutics, including Exosomes, Nanocomplexes and Platform Delivery Approaches and patenting RNA Therapeutics. www.therapeutics-rna.com/opr Spotlight: Want to learn about exploiting exosomes for therapeutic use in patients with cystic fibrosis? Have questions answered during
RNA Analysis Market worth 3.62 billion USD by 2021
RNA Analysis Market size was around USD 1.89 billion in 2016. It is expected to grow at a CAGR of 13.9% to reach USD 3.62 billion by 2021. The market is mainly driven by the increasing technological advancements, increasing investment in research and development by biotechnology and pharmaceutical companies, rising government and private funding, and growing preference for personalized medicines. However, lack of skilled professionals in the transcriptomics field and lack
New Confirmed Delegates & Speakers for RNA Therapeutics
SMi are thrilled to welcome Dr. James Hamilton, Vice President, Head of Clinical Development, Arrowhead Pharmaceuticals onto the speaker panel RNA Therapeutics 2018! Dr. James Hamilton is currently responsible for all aspects of clinical trial design, implementation and execution. In this role, Dr. Hamilton managed the ARC-520 and ARC-AAT global programs through Phase 2 of development. Previously, Dr. Hamilton was Medical Director and Head of Corporate Development at Arrowhead. He led